Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Genakumab Injection vs Powder in Healthy Chinese Males
NCT06451848Phase 1Completed
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Jun 2024
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of genakumab in gouty arthritis (2 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Area under the concentration-time curve, Peak Plasma Concentration and 2 more. Started Jun 2024; status: completed.
02
Drugs
genakumab
03
Conditions
gouty arthritis
Beyond the preview
Go deeper on NCT06451848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06451848.